Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our top-notch dedicated system is used to design specialised libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
Q9UHC9

UPID:
NPCL1_HUMAN

ALTERNATIVE NAMES:
Niemann-Pick C1-like protein 1

ALTERNATIVE UPACC:
Q9UHC9; A4D2J7; B7ZLE6; D3DVK9; Q17RV5; Q6R3Q4; Q9UHC8

BACKGROUND:
The protein NPC1-like intracellular cholesterol transporter 1, alternatively known as Niemann-Pick C1-like protein 1, is critical for cholesterol absorption and homeostasis. It transports cholesterol and sitosterol across the intestinal membrane and influences lipid metabolism. Ezetimibe, a hypercholesterolemia treatment, targets this protein. It also regulates NPC2 expression and secretion, impacting lipid transport and homeostasis.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of NPC1-like intracellular cholesterol transporter 1 may lead to innovative therapeutic approaches.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.